UNSPSC 51373005: Moxazocine

This classification denotes an analgesic agent with the molecular formula C18H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BNB57S7DWT, chemically known as 2,6-methano-3-benzazocin-8-ol, 3-(cyclopropyl-methyl)-1,2,3,4,5,6-hexahydro-11-methoxy-6-methyl-,(2r-(2 alpha, 6 alpha, 11r*))-; but generally known as moxazocine, which bears US NIH Compound Identifier 3047776. European Medicines Agency schedules Moxazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09083MIG.

UNSPSC 51373005 Moxazocine is a Commodity code under which state and local governments procure pharmaceutical products—in recent activity, primarily naloxone and generic multi-source pharmaceuticals for community health and pharmacy benefit programs. The code reflects naloxone acquisition for overdose response and broader pharmaceutical supply chain management across health departments, county health systems, and state pharmacy benefit administrators. Issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving participating state and local facilities across multiple states including Oregon). The work solicited ranges from direct naloxone procurement in fixed quantities to manufacturer-level contracts supplying generic pharmaceuticals and over-the-counter products through established wholesaler channels, with vendors required to meet Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, and specific insurance thresholds.

Geographic activity centers on Florida and Texas, with multi-state cooperative reach extending to Oregon and other MMCAP participant jurisdictions. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs and therapy-management capabilities; and Minnesota Department of Administration's MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multi-award contracts for generic pharmaceuticals and OTC products across authorized wholesalers, with pricing weighted at 75 percent of evaluation and contract terms through July 1, 2028. Vendors pursuing this code face compliance demands including E-Verify, FEMA funding adherence where applicable, and performance penalties on wholesale fulfillment contracts; cooperative purchasing vehicles dominate the multi-state landscape and reduce per-entity procurement friction.